Following approval by an internal FDA review panel, the Johnson & Johnson adenovirus vector COVID vaccine was approved by the external review panel and the CDC and should be available for shipping during the first week in March.  The single-dose vaccine can be stored and transported at conventional refrigeration temperature.  Approximately 20 million doses of the vaccine are expected by the end of the March and the company is contracted to supply 100 million doses by the end of June with an option to purchase an additional 200 million doses.